Biological agents and gemcitabine in the treatment of breast cancer.
Morandi
P
P
Michelangelo Foundation, Medical Oncology Department, S Bortolo Hospital, Vicenza, Italy. paolomorandi1@tin.it
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001685:Biological Factors / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D000093542:Gemcitabine
D001685:Biological Factors; D004791:Enzyme Inhibitors; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D051231:Farnesyltranstransferase; C512478:EGFR protein, human; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000093542:Gemcitabine